Purpose: Four recent first-line clinical trials leveraging immune-oncology agents
demonstrated an overall survival (OS) benefit relative to sunitinib. We aimed to provide formal …

Background: Renal cell carcinoma (RCC) is a common malignancy with approximately 30%
of cases diagnosed at the advanced or metastatic stage. While single-agent vascular …

Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients
have yet to receive durable benefits. Here, in order to investigate the metabolic alterations …

Conclusion Herein, we comprehensively review and refine the clinical hallmarks uniquely
associated with ICI therapies, which not only will rejuvenate our assessment of ICI therapeutic …

Context Systemic therapy for metastatic clear cell renal cell carcinoma (mccRCC) has greatly
evolved over the last 15 yr. More recently, combination strategies involving contemporary …

Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the
past decade, several new treatments for advanced prostate cancer have been approved. …

… Aly-Khan Lalani: grants/research support (all funds to institution)—BMS (Inst), BioCanRx (Inst),
Novartis (Inst), Roche (Inst), Ipsen (Inst), and EMD Serono (Inst); honoraria—AbbVie, …

Background Antibiotic use alters commensal gut microbiota, which is a key regulator of immune
homeostasis. Objective To investigate the impact of antibiotic use on clinical outcomes in …

Background and objective Metastatic renal cell carcinoma (mRCC) patients have been reported
to have better outcomes when treated with immunotherapies (IO) compared to targeted …

There has been a considerable increase in the variety of effective therapies for mUC,
including the utility of ICIs, novel targeted agents, and ADCs. Platinum-based chemotherapy …